Cibus, Inc. 8-K

What Happened

• Cibus, Inc. announced on June 8, 2026 that the Board appointed Craig Wichner as Chief Executive Officer, effective that date. Mr. Wichner, age 56, joined Cibus’ Board in November 2025 and concurrently resigned from the Board and its Strategy Committee upon becoming CEO. Peter Beetham returned from Interim CEO to President and Chief Operating Officer on June 8, 2026 and resigned from the Board as part of the transition.

Key Details

• Initial base salary for Mr. Wichner: $650,000; eligible for discretionary annual bonus and annual incentive equity awards.
• Equity grants on June 8, 2026: RSUs with grant-date fair value $1,100,000 and stock option with grant-date fair value $1,100,000; each vests 25% on each of the first four anniversaries; option term 10 years and exercise price = fair market value at grant.
• Severance protections: if terminated without Cause or resigns for Good Reason, 18 months of base pay, vesting for equity that would vest in that period, unpaid earned bonus, and up to 18 months COBRA; in a Change in Control, benefits increase to 24 months pay, full vesting of all equity, and up to 24 months COBRA.
• Governance change: Mr. Wichner and Dr. Beetham resigned from the Board; authorized number of directors reduced to seven. A company press release about the leadership changes was issued June 8, 2026.

Why It Matters

• Leadership: The appointment makes the previously announced succession plan explicit — a new permanent CEO with experience in farmland investment and sustainable agriculture (founder/managing partner of Farmland LP) could shape strategic focus and R&D priorities.
• Compensation and incentives: The CEO’s significant equity grants and severance protections align pay with long-term performance and retention, and may affect future share-based dilution and executive costs.
• Governance: Board resignations and a reduction in directors signal a board refresh intended to enhance independence — a material governance change investors monitor for oversight quality and strategic direction.
• Cash impact: Base salary and reduced salary for Dr. Beetham (from $650,000 to $585,000 for 2026) affect near-term cash compensation expenses; long-term impacts depend on bonus awards and equity vesting.